ReviewCurrent neurology and neuroscience reports2016
An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma.
Review in Current neurology and neuroscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4CNS oncology · 2018Trial
- Tumor treating fields alter local coagulation dynamics in glioblastoma patients.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Tumor-treating fields and concurrent cisplatin: anAmerican journal of cancer research · 2025Article
- Hydrogel and scalp/skin conductivities impact dose from tumor treating fields.Frontiers in bioengineering and biotechnology · 2025Article
- A qualitative evaluation of factors influencing Tumor Treating fields (TTFields) therapy decision making among brain tumor patients and physicians.BMC cancer · 2024Article
- Electric field modulation of ERK dynamics shows dependency on waveform and timing.Scientific reports · 2024Article
- Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells.Scientific reports · 2023Article
- Review
- Optimization of tumor-treating field therapy for triple-negative breast cancer cells in vitro via frequency modulation.Cancer cell international · 2023Article
- Efficacy and selectivity of tumor-treating field therapy for triple-negative breast cancer cells via in-house delivery device.Discover oncology · 2023Article
- Extracranial metastasis of glioblastoma with genomic analysis: a case report and review of the literature.Translational cancer research · 2022Article
- An overview on tumor treating fields (TTFields) technology as a new potential subsidiary biophysical treatment for COVID-19.Drug delivery and translational research · 2022Review
- Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study.CNS neuroscience & therapeutics · 2021Article
- Clinical Potential of Nerve Input to Tumors: A Bioelectricity Perspective.Bioelectricity · 2021Article
- Cytotoxic T cells response with decreased CD4/CD8 ratio during mammary tumors inhibition in rats induced by non-contact electric fields.F1000Research · 2021Article
- Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy.American journal of cancer research · 2021Article
- Novel Electrode Designs for Neurostimulation in Regenerative Medicine: Activation of Stem Cells.Bioelectricity · 2020Review
- The Value of Tumor Treating Fields in Glioblastoma.Journal of Korean Neurosurgical Society · 2020Article
- Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment.Scientific reports · 2020Article
- Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As with many cancer treatments, tumor treating fields (TTFields) target rapidly dividing tumor cells. During mitosis, TTFields-exposed cells exhibit uncontrolled membrane blebbing at the onset of anaphase, resulting in aberrant mitotic exit. Based on these criteria, at least two protein complexes have been proposed as TTFields' molecular targets, including α/β-tubulin and the septin 2, 6, 7 heterotrimer. After aberrant mitotic exit, cells exhibited abnormal nuclei and signs of cellular stress, including decreased cellular proliferation and p53 dependence, and exhibit the hallmarks of immunogenic cell death, suggesting that TTFields treatment may induce an antitumor immune response. Clinical trials lead to Food and Drug Administration approval for their treatment of recurrent glioblastoma. Detailed modeling of TTFields within the brain suggests that the location of the tumor may affect treatment efficacy. These observations have a profound impact on the use of TTFields in the clinic, including what co-therapies may be best applied to boost its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.